SCHEMBL3449673

SCHEMBL3449673

O=C(O)C=Cc1cccc(-c2cnc(Nc3ccc(F)c(Cl)c3)nc2-n2ccnn2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM2 Q9P1W9 2/20 0.39
CSNK1A1 P48729 1/20 0.39
FYN P06241 1/20 0.37
EGFR P00533 3/20 0.37
AURKA O14965 1/20 0.37
GSK3A P49840 1/20 0.37
GSK3B P49841 1/20 0.37
RHOA P61586 1/20 0.36
ABL1 P00519 1/20 0.35
BCR P11274 1/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
BTK Q06187 1/20 0.35
MAPK1 P28482 2/20 0.34
NAMPT P43490 1/20 0.34
FGFR1 P11362 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3449670 1.00 PIM2 (0.39) PIM2CSNK1A1FYNEGFRAURKA
SCHEMBL3448082 0.91 PIM2 (0.40) PIM2CSNK1A1FYNEGFRAURKA
SCHEMBL3448079 0.91 PIM2 (0.40) PIM2CSNK1A1FYNEGFRAURKA
SCHEMBL13310998 0.89 P2RX3 (0.36) CSNK1A1EGFRABL1BCRBTK
SCHEMBL3448518 0.88 PIM2 (0.40) PIM2CSNK1A1FYNEGFRAURKA
SCHEMBL3448515 0.88 PIM2 (0.40) PIM2CSNK1A1FYNEGFRAURKA
SCHEMBL3448627 0.87 CSNK1A1 (0.38) PIM2CSNK1A1FYNEGFRAURKA
SCHEMBL3448631 0.87 CSNK1A1 (0.38) PIM2CSNK1A1FYNEGFRAURKA
SCHEMBL3447210 0.87 PIM2 (0.41) PIM2CSNK1A1FYNEGFRAURKA
SCHEMBL3447212 0.87 PIM2 (0.41) PIM2CSNK1A1FYNEGFRAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD PIM2 3060/4885CSNK1A1 1378/4885FYN 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.